Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site.

@article{Akk2005GalantamineAM,
  title={Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site.},
  author={Gustav Akk and Joe Henry Steinbach},
  journal={The Journal of neuroscience : the official journal of the Society for Neuroscience},
  year={2005},
  volume={25 8},
  pages={1992-2001}
}
Galantamine (Reminyl; Janssen Pharmaceutica, Titusville, NJ) belongs to a class of acetylcholinesterase inhibitors approved for symptomatic treatment of Alzheimer's disease. The drug presumably acts by raising and prolonging the profile of acetylcholine (ACh) via an inhibitory effect on the esterase. However, there is also evidence demonstrating that galantamine can activate the nicotinic ACh receptor or modulate its activation by ACh. In this study, we have examined the ability of galantamine… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Physiological characterization of human muscle acetylcholine receptors from ALS patients.

Proceedings of the National Academy of Sciences of the United States of America • 2011
View 2 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Similar Papers

Loading similar papers…